Phase II study of maytansine in advanced breast cancer.
作者信息
Edmonson J H, Rubin J, Kvols L K, O'Connell M J, Frytak S, Green S J
出版信息
Cancer Treat Rep. 1981 May-Jun;65(5-6):536-7.
PMID:7237478
Abstract
摘要
相似文献
1
Phase II study of maytansine in advanced breast cancer.
Cancer Treat Rep. 1981 May-Jun;65(5-6):536-7.
2
Results of a phase II study of maytansine in patients with breast carcinoma and melanoma.
Cancer Treat Rep. 1979 Mar;63(3):507-9.
3
Phase II study of maytansine in advanced sarcomas.
Cancer Treat Rep. 1983 Apr;67(4):401-2.
4
Phase II evaluation of maytansine in patients with advanced head and neck cancer.
Cancer Treat Rep. 1979 Nov-Dec;63(11-12):2061-2.
5
Phase II evaluation of maytansine in patients with metastatic lung cancer.
Cancer Treat Rep. 1978 Oct;62(10):1577-9.
6
Phase II trial of maytansine in patients with advanced colorectal carcinoma.
Cancer Treat Rep. 1978 Aug;62(8):1237-8.
7
Phase II study of maytansine in patients with advanced lymphomas: an Eastern Cooperative Oncology Group pilot study.
Cancer Treat Rep. 1980 Oct-Nov;64(10-11):1115-7.
8
Maytansine: a phase I study of an ansa macrolide with antitumor activity.
Cancer Treat Rep. 1978 Mar;62(3):435-8.
9
Minimal single-agent activity of maytansine in refractory breast cancer: a Southwest Oncology Group study.
Cancer Treat Rep. 1980 Apr-May;64(4-5):675-7.
10
Initial clinical trials of maytansine, an antitumor plant alkaloid.
Cancer Treat Rep. 1978 Mar;62(3):429-33.
引用本文的文献
1
The Yunnan national medicine Maytenus compound inhibits the proliferation of hepatocellular carcinoma (HCC) by suppressing the activation of the EGFR-PI3K-AKT signaling pathway.
J Cancer. 2021 Apr 7;12(11):3325-3334. doi: 10.7150/jca.56426. eCollection 2021.
2
Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products.
Drugs. 2015 Nov;75(17):1993-2016. doi: 10.1007/s40265-015-0489-4.
Zotero 插件